Shukui Qin

51.6k total citations · 12 hit papers
337 papers, 12.0k citations indexed

About

Shukui Qin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Shukui Qin has authored 337 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Oncology, 163 papers in Pulmonary and Respiratory Medicine and 116 papers in Hepatology. Recurrent topics in Shukui Qin's work include Hepatocellular Carcinoma Treatment and Prognosis (114 papers), Colorectal Cancer Treatments and Studies (83 papers) and Lung Cancer Treatments and Mutations (68 papers). Shukui Qin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (114 papers), Colorectal Cancer Treatments and Studies (83 papers) and Lung Cancer Treatments and Mutations (68 papers). Shukui Qin collaborates with scholars based in China, United States and South Korea. Shukui Qin's co-authors include Masatoshi Kudo, Ann‐Lii Cheng, Yuxian Bai, Andrew X. Zhu, Yoon‐Koo Kang, Jianming Xu, Peter R. Galle, Richard S. Finn, Ho Yeong Lim and Hongming Pan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Shukui Qin

326 papers receiving 11.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Ann‐Lii Cheng, Shukui Qin et al. profile →
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

2013 586 citations Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology profile →
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 553 citations Jin Li, Shukui Qin et al. profile →
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

2014 465 citations Shukui Qin, Hongming Pan et al. Journal of Clinical Oncology profile →
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

2014 438 citations Shukui Qin, Yoon‐Koo Kang et al. Journal of Clinical Oncology profile →
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Shukui Qin, Zhenggang Ren et al. profile →
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

2013 417 citations Shukui Qin, Jianming Xu et al. Journal of Clinical Oncology profile →
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

2019 409 citations Masatoshi Kudo, Stephen L. Chan et al. profile →
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

2013 366 citations Shukui Qin, Yuxian Bai et al. Journal of Clinical Oncology profile →
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

2023 136 citations Shukui Qin, Masatoshi Kudo et al. profile →
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

2024 93 citations Riccardo Lencioni, Masatoshi Kudo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Shukui Qin

Since Specialization

Citations

This map shows the geographic impact of Shukui Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shukui Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shukui Qin more than expected).

Fields of papers citing papers by Shukui Qin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shukui Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shukui Qin. The network helps show where Shukui Qin may publish in the future.

Co-authorship network of co-authors of Shukui Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Shukui Qin. A scholar is included among the top collaborators of Shukui Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shukui Qin. Shukui Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive performance evaluation of Zigzag mini-channel for printed circuit heat exchanger 2025 ·Applied Thermal Engineering ·Yu‐Cai Zhang, Shukui Qin, Wenchun Jiang, Xian‐Cheng Zhang, Shan‐Tung Tu	0
2	Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis 2025 ·EClinicalMedicine ·(unknown), Jinren Pan, (unknown), Zhiwen Jin, Shijian Li, Hangjie Zhang, (unknown), (unknown), Yu Zhao, Shukui Qin, Xiaoying Xu, Yin Chen, (unknown), Shelan Liu	1
3	First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial 2025 ·European Journal of Cancer ·Maeve A. Lowery, Lucjan Wyrwicz, Do‐Youn Oh, Kai‐Keen Shiu, Patricio Yañez, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, (unknown), Jin Li, Timuçin Çil, Felipe José Silva Melo Cruz, Shukui Qin, (unknown), Adriana Valderrama, Sonal Bordia, Sun Young Rha	0
4	Chronic Sleep Deprivation Altered the Expression of Memory-Related Genes and Caused Cognitive Memory Dysfunction in Mice 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Tian Tang, (unknown), Shukui Qin, Taijun Hang, Min Song	4
5	Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Stephen L. Chan, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Yasuaki Arai, В. В. Бредер, Shi-Ming Lin, Jean‐Marie Péron, Tien Quang Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda Santos, (unknown), Satheesh Chiradoni Thungappa, Claire Morgan, Kerry Parsons, Ioannis Xynos, Riccardo Lencioni	4
6	Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Shukui Qin, Ying Cheng, Qiming Wang, (unknown), Xiaoli Chai, Lihua Wu, Yan Yu, (unknown), (unknown), (unknown), (unknown), Yisheng Huang, Yinghua Ji, Zhixiang Zhuang, Lei Yang, (unknown), (unknown), Sihai Liao, Shanyong Yi, (unknown)	0
7	A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy 2024 ·International Journal of Nanomedicine ·(unknown), (unknown), Zhuo Chen, (unknown), (unknown), (unknown), Shukui Qin, (unknown), Ming Luo, Yang Jin, (unknown), Bo Li, Xiaoli Yang	12
8	Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. 2024 ·Journal of Clinical Oncology ·(unknown), Stephen L. Chan, Zhenggang Ren, Yuxian Bai, Shanzhi Gu, (unknown), Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, (unknown), Monika Pazgan−Simon, (unknown), (unknown), Haisong Zhang, (unknown), Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin, (unknown)	16
9	O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer 2023 ·Annals of Oncology ·Lucjan Wyrwicz, Do‐Youn Oh, (unknown), Yuxian Bai, Min‐Hee Ryu, (unknown), Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, (unknown), J. Li, (unknown), (unknown), (unknown), Shukui Qin, Lei Yin, Sonal Bordia, Pooja Bhagia, Sun Young Rha	3
10	Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer 2023 ·Future Oncology ·Shukui Qin, Tianshu Liu, Jianming Xu, (unknown), Ying Cheng, (unknown), Regina Esser, Helena R. Chang, Jin Li	4
11	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial breakdown → 2022 ·Journal of Clinical Oncology ·Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaohong Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao	127
12	Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis 2022 ·Integrative Cancer Therapies ·(unknown), Xia Zheng, Wenming Li, Hongyu Deng, Shukui Qin	12
13	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). 2021 ·Journal of Clinical Oncology ·Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun‐Wook Lee, Sang Cheul Oh, Jin Li, Hacı Mehmet Türk, Alexandra Teixeira, Giovanni Gerardo Cardellino, (unknown), Siddhartha Mitra, Yingsi Yang, Helen Collins, Daniel V.T. Catenacci	63
14	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression 2021 ·British Journal of Cancer ·Baek‐Yeol Ryoo, Ann‐Lii Cheng, Zhenggang Ren, Tae‐You Kim, Hongming Pan, Kun-Ming Rau, Hye Jin Choi, Joong‐Won Park, Jee Hyun Kim, (unknown), Ho Yeong Lim, Dongli Zhou, Josef Straub, (unknown), Karin Berghoff, Shukui Qin	36
15	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT 2021 ·Journal of Gastroenterology ·Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Ann‐Lii Cheng, Fabio Piscaglia, Masahiro Kobayashi, Max W. Sung, Minshan Chen, Lucjan Wyrwicz, Jung‐Hwan Yoon, Zhenggang Ren, Kalgi Mody, Corina E. Dutcus, Toshiyuki Tamai, Min Ren, Seiichi Hayato, Hiromitsu Kumada	10
16	Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE) 2021 ·The Oncologist ·Shukui Qin, Jiafu Ji, Rui‐Hua Xu, Wei Wang, Yong Tang, Feng Bi, Jin Li, Kang Wang, Jianming Xu, Qingxia Fan, (unknown), Lin Shen	23
17	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2‐positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial 2019 ·Cancer Communications ·Tianshu Liu, Yanru Qin, Jin Li, Rui‐Hua Xu, Jianming Xu, Shujun Yang, Shukui Qin, Yuxian Bai, Changping Wu, Yixiang Mao, Haiyan Wu, Yilin Ge, Lin Shen	23
18	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges 2019 ·The Oncologist ·Xiufeng Liu, Shukui Qin	107
19	[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. 2013 ·PubMed ·Lin Shen, (unknown), (unknown), (unknown), (unknown), Jin Li, (unknown), Shukui Qin, (unknown), (unknown), (unknown), (unknown), Min Tao, (unknown), (unknown)	18
20	Cathepsin L Plays a Role in Quinolinic Acid-Induced NF-Κb Activation and Excitotoxicity in Rat Striatal Neurons 2013 ·PLoS ONE ·(unknown), (unknown), Shukui Qin, Rong Han, Junchao Wu, Zhong‐Qin Liang, Zheng‐Hong Qin, Yan Wang	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact